HOME >> BIOLOGY >> NEWS
Think twice before exercising when getting that PET scan

metabolize sugar at higher rates than normal cells, the radiopharmaceutical is drawn in higher concentrations (called "uptake") to cancerous areas. The PET scan shows where the radiopharmaceutical is by tracking the gamma ray signals given off by the radionuclides. PET scans are very sensitive, and increased physical activity can create problems in differentiating between normal and pathologic uptake, explained Osman. Normal muscles accumulate little FDG, but muscles exercised just before or around the time of the scanning can exhibit intense uptake into those muscles--for example, possibly mimicking cancer, he added.

The study advises technologists to instruct patients to minimize muscle activity during the uptake phase and to telephone patients ahead of their appointments to advise them to refrain from any excessive muscle activity at least 48 hours before a PET scan. The study's findings emphasize that the accuracy of studies for patients can be improved through educating technologists of the relationship between muscle activity and uptake and in coordinating a team approach with physicians, said Schlarman. "Technologists play a major role in informing physicians of patients' activity" that could skew the reading of their PET scans, Osman said. "Any unexpected or unexplained excessive muscle uptake should initiate communications between technologists and reading physicians to avoid false-positive PET scan interpretations," he added.

The team of technologist and physician researchers in St. Louis--all SNM or SNM Technologist Section members--studied the whole-body PET scans of more than 1,100 cancer patients over a one-year period. Of those patients, nearly 13 percent had excessively increased muscle uptake on the PET scan that matched technologists' notes of muscle activity during the uptake phase or prior to scanning. Increased uptake was seen in individuals' head and neck, thorax and upper extremities, indicating the influence of activities s
'"/>

Contact: Maryann Verrillo
mverrillo@snm.org
703-708-9000
Society of Nuclear Medicine
8-Mar-2006


Page: 1 2 3

Related biology news :

1. Green Nanotechnology: Its Easier Than You Think
2. Think herbal supplements are safe? Think again, book by Saint Louis University doctor says
3. Thinking big about things small
4. Thinking with the spinal cord?
5. Think fast! Rice undergrad unlocks nerve speed secret
6. Thinking the pain away? Study shows the brains painkillers may cause placebo effect
7. Thinking small: Texas A&M team creates lab-on-a-chip
8. The insect vector always bites twice
9. Individuals with genetic conditions twice as likely to report health insurance denial
10. Minimal genome should be twice the size, study shows
11. Investigational therapy denosumab increased bone mineral density with twice-yearly dosing

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Think twice before exercising when getting that PET scan

(Date:10/18/2014)... suspected genetic conditions, a certain type of exome sequencing ... than traditional molecular diagnostic methods, according to a study ... released to coincide with the American Society of Human ... protein­coding region of the genome (the complete set of ... organism), has been rapidly applied in research settings and ...
(Date:10/17/2014)... release is available in German . ... of sperms every day in order to reproduce? And why ... the topic of the latest issue of the research journal ... The evolutionary biologist Steven Ramm from Bielefeld University Bielefeld has ... is not unusual for a female to copulate with several ...
(Date:10/17/2014)... To date, antidotes ... doctors are often limited to supportive therapy such as induced ... of drugs involved. So what can be done if a ... professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences at ... "The task was to develop an agent that could eliminate ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Sperm wars 2Emergency aid for overdoses 2Emergency aid for overdoses 3
(Date:10/22/2014)... Oct. 22, 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, announced today that ... Notice of Allowance for a composition of matter patent ... difficile program, SYN-004. This is Synthetic Biologics, first ... U.S. and adds to the Company,s extensive C. ...
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... BOSTON , Oct. 20, 2014 ... commercialization company tackling big healthcare problems, announced today ... investment round, with participation from Invesco Perpetual, a ... be used to drive PureTech,s existing pipeline forward ... technologies. "PureTech has the scientific creativity to really ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
Cached News: